292 related articles for article (PubMed ID: 27327292)
1. Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy.
Kovach JL; Hess H; Rosenfeld PJ
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):593-5. PubMed ID: 27327292
[TBL] [Abstract][Full Text] [Related]
2. Progressive Release of Vitreomacular Traction With Aflibercept.
Schwartz SG; Flynn HW
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):477-81. PubMed ID: 27183554
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
4. Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept.
Calvo CM; Sridhar J; Shahlaee A; Ho AC
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):474-6. PubMed ID: 27183553
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
6. Significant Bilateral Response in Diabetic Macular Edema After Single Unilateral Intravitreal Aflibercept Injection.
Rahimy E; Nyong'o O; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2017 Feb; 48(2):167-169. PubMed ID: 28195620
[TBL] [Abstract][Full Text] [Related]
7. EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.
Kowalczuk L; Matet A; Dirani A; Daruich A; Ambresin A; Mantel I; Spaide RF; Turck N; Behar-Cohen F
Retina; 2017 Dec; 37(12):2226-2237. PubMed ID: 28002269
[TBL] [Abstract][Full Text] [Related]
8. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept Treatment for Macular Edema following Branch Retinal Vein Occlusion: Age-Based Responses.
Sırakaya E; Küçük B; Ağadayı A
Ophthalmologica; 2020; 243(2):94-101. PubMed ID: 31461723
[TBL] [Abstract][Full Text] [Related]
10. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
Blindbæk SL; Peto T; Grauslund J
Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608
[TBL] [Abstract][Full Text] [Related]
11. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
[TBL] [Abstract][Full Text] [Related]
12. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
[TBL] [Abstract][Full Text] [Related]
14. One-year treatment outcomes of ziv-aflibercept for treatment-naïve macular oedema in branch retinal vein occlusion.
Chan EW; Eldeeb M; Dedhia CJ; Mansour A; Chhablani J
Acta Ophthalmol; 2018 Mar; 96(2):e256-e257. PubMed ID: 28371171
[No Abstract] [Full Text] [Related]
15. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
16. Twenty-Four-Month OCTA Assessment in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy.
Statler B; Conti TF; Conti FF; Silva FQ; Rachitskaya A; Yuan A; Schachat A; Kaiser PK; Singh RP; Babiuch A
Ophthalmic Surg Lasers Imaging Retina; 2020 Aug; 51(8):448-455. PubMed ID: 32818277
[TBL] [Abstract][Full Text] [Related]
17. Subthreshold Micropulse Yellow Laser (577 nm) for Idiopathic Macular Telangiectasia Type 1 Resistant to Intravitreal Injection.
Kang YK; Park HS
Korean J Ophthalmol; 2020 Apr; 34(2):168-169. PubMed ID: 32233152
[No Abstract] [Full Text] [Related]
18. Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema.
Ashraf M; Kayal HE; Souka AAR
Ophthalmic Surg Lasers Imaging Retina; 2017 May; 48(5):399-405. PubMed ID: 28499051
[TBL] [Abstract][Full Text] [Related]
19. Fluorescein Angiography Versus Optical Coherence Tomography Angiography in Macular Telangiectasia Type I Treated With Bevacizumab Therapy.
Yannuzzi NA; Gregori NZ; Roisman L; Gupta N; Goldhagen BE; Goldhardt R
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):263-266. PubMed ID: 28297041
[TBL] [Abstract][Full Text] [Related]
20. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
